公开(公告)号：US20250064724A1

公开(公告)日：2025-02-27

申请号：US18718963

申请日：2022-11-18

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Martin J. MANGINO ,  Loren K. LIEBRECHT ,  Jad KHORAKI

IPC: A61K9/00 ,  A61K31/198 ,  A61K38/36 ,  A61K47/02 ,  A61K47/10 ,  A61P7/00

Abstract: Bio-artificial blood substitutes are provided for intravenous medical use to restore or increase tissue perfusion and oxygen delivery in a pre-hospital or hospital setting. The bio-artificial blood substitutes comprise three modular components (polyethylene glycol (PEG) polymers to increase perfusion, a hemoglobin-based oxygen carrier (HBOC) plus L-arginine to prove oxygen carrying capacity, and a lyophilized fibrinogen or plasma component to provide hemostasis potential, all of which are administered sequentially in modules to treat low perfusion states with possible coagulopathy as seen in blood loss and shock. The three solutions are stable at ambient temperature and are well-suited for use in the field, e.g., when immediate, critical care is needed such as on the battlefield, during natural disasters or other mass casualty events. Other use may include clinical need for transfusion or for peri-surgical resuscitation in patients unable to receive standard blood products.

公开(公告)号：US20220387478A1

公开(公告)日：2022-12-08

申请号：US17761792

申请日：2020-09-23

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Martin J. MANGINO ,  Loren K. LIEBRECHT

IPC: A61K31/765 ,  A61K47/08 ,  A61K9/08

Abstract: A composition for restoring or increasing tissue perfusion is provided. The composition includes polyethylene glycol polymers (PEG) with a molecular weight of 18,000-100,000 Da at a concentration of 5-20% by weight; PEG with a molecular weight of 1,000-10,000 Da at a concentration of 1-30% by weight; and water, wherein said PEG with a molecular weight of 18,000-100,000 Da and said PEG with a molecular weight of 1,000-10,000 Da are dissolved or dispersed in said water.